| ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. | |
| | |
MedLine Citation:
|
PMID: 20408782 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
K-RAS mutation is being developed as a cancer biomarker and tumor K-RAS is being used to predict therapeutic response. Yet, levels of K-RAS mutation in normal and pathological tissue samples have not been determined rigorously, nor inter-individual variation in these levels characterized. Therefore, K-RAS codon 12 GAT and GTT mutant fractions were measured in colonic mucosa of individuals without colon cancer, tumor-distal mucosa, tumor-proximal mucosa, normal tumor-adjacent tissues, colonic adenomas, and carcinomas. The results indicate K-RAS codon 12 GAT mutation is present at measurable levels in normal appearing mucosa. All tumors carried K-RAS mutation, in most cases as a mutant subpopulation. |
| | |
Authors:
|
Barbara L Parsons; Kathryn E Marchant-Miros; Robert R Delongchamp; Tracie L Verkler; Tucker A Patterson; Page B McKinzie; Lawrence T Kim |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Cancer investigation Volume: 120 ISSN: 1532-4192 ISO Abbreviation: Cancer Invest. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8307154 Medline TA: Cancer Invest Country: England |
Other Details:
|
Languages: eng Pagination: 364-75 Citation Subset: IM |
Affiliation:
|
US FDA, National Center for Toxicological Research, Jefferson, Arkansas, USA. barbara.parsons@fda.hhs.gov <barbara.parsons@fda.hhs.gov> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activit...
Next Document: Prognostic value of the t(14;18)(q32;q21) in patients with diffuse large B-cell lymphoma.